Trial Profile
To evaluate the immune response to Pneumococcal Conjugate Vaccine (PCV13) in patients with Chronic Lymphocytic Leukemia recieving Ibrutinib
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Jan 2017
Price :
$35
*
At a glance
- Drugs Pneumococcal vaccine conjugate (Primary) ; Ibrutinib
- Indications Pneumococcal infections
- Focus Therapeutic Use
- 16 Jan 2017 New trial record
- 06 Dec 2016 Interim results (n=9) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.